Another study showed that high percentage of CD8+ TILs that were PD-1+TIM-3−LAG-3− correlated with high levels of T-cell activation and was associated with better PFS and OS in metastatic clear cell renal cell carcinoma treated with nivolumab (33). The gene discussed is CD8A; the disease is clear cell renal carcinoma.